Form 6-K Pharming Group N.V. For: Oct 14

Wed, 14 Oct 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20261014/27183231.html

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Wed, 14 Oct 2026 02:00:00 -0400

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation
Leniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markers
All participants who completed the study elected to continue receiving treatment in a long-term extension study

Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Wed, 14 Oct 2026 02:00:00 -0400

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation
Leniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markers
All participants who completed the study elected to continue receiving treatment in a long-term extension study

Form 6-K Pharming Group N.V. For: Sep 29

Tue, 29 Sep 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260929/27117027.html

Pharming CEO steps down; interim co-CEOs named

Tue, 29 Sep 2026 01:00:09 -0400

Pharming Group N.V. (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announced that Fabrice Chouraqui has stepped down as Chief Executive Officer and Executive Director by mutual agreement with the Board of Directors, effective immediately.

The Board has appointed Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard as Interim Co-CEOs. Marsh will oversee patient-focused operations, while Lynard will lead global corporate functions. The Board has begun a formal search for a permanent CEO.

According to the announcement, the Board and Chouraqui concluded their views on executing the company's strategic priorities were not sufficiently aligned, prompting the leadership change.

Board Chairman Richard Peters

Pharming announces CEO transition

Tue, 29 Sep 2026 01:00:00 -0400

Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board

Pharming announces CEO transition

Tue, 29 Sep 2026 01:00:00 -0400

Form 6-K Pharming Group N.V. For: Sep 25

Fri, 25 Sep 2026 11:12:00 -0400

si-local-file:///var/storage/secattach/20260925/27105302.html

FDA accepts Pharming's sNDA for Joenja in lower-weight children

Fri, 25 Sep 2026 10:30:18 -0400

Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking approval for lower doses of Joenja® (leniolisib) for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act target action date of January 30, 2027. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the effectiveness or safety of

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Fri, 25 Sep 2026 10:30:00 -0400

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more
Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg
PDUFA target action date of January 30, 2027

Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Fri, 25 Sep 2026 10:30:00 -0400

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more
Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg
PDUFA target action date of January 30, 2027

Canaccord Reiterates Buy Rating on Pharming Group (PHAR)

Wed, 23 Sep 2026 06:42:27 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $38.00 price target on Pharming Group (NASDAQ: PHAR).

The analyst commented: 'Overnight, PHAR announced positive topline Phase II data for Joenja (leniolisib) in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling. The study showed clinical improvements across measures of immune dysregulation, including lymphoproliferative disease, with a mean 26.4% (n=13) reduction in spleen volume and reductions in index lesion size. This is consistent with the spleen-volume benefit seen with Joenja's approved APDS indication where Joenja showed a 26.68% mean reduction in 3D spleen volume at week 12 (n=19) versus

Form 6-K Pharming Group N.V. For: Sep 22

Tue, 22 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260922/27087124.html

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Tue, 22 Sep 2026 01:00:00 -0400

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation
Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026

Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Tue, 22 Sep 2026 01:00:00 -0400

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation
Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026

Form 6-K Pharming Group N.V. For: Sep 11

Fri, 11 Sep 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260911/27052571.html

FDA approves Pharming's Joenja for children ages 4 to 11 with APDS

Fri, 11 Sep 2026 14:00:16 -0400

The U.S. Food and Drug Administration has approved a supplemental New Drug Application from Pharming Group N.V. (Euronext Amsterdam: PHARM, Nasdaq: PHAR) for 40 mg and 50 mg twice-daily doses of Joenja (leniolisib) to treat children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome, known as APDS, a rare primary immunodeficiency.

The approval, announced September 11, 2026, expands the existing Joenja indication, which the FDA first granted in March 2023 for adults and pediatric patients 12 years and older. According to the company, the newly approved doses are expected to be available through

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Fri, 11 Sep 2026 14:00:00 -0400

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
Newly approved Joenja doses are expected to be available in October

Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor,

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Fri, 11 Sep 2026 14:00:00 -0400

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
Newly approved Joenja doses are expected to be available in October

Pharming Group to participate in September investor conferences

Wed, 09 Sep 2026 02:00:00 -0400

Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September:

H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026
Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026

Pharming Group to participate in September investor conferences

Wed, 09 Sep 2026 02:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026
Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Pharming Group (PHAR) PT Raised to $38 at Canaccord

Mon, 03 Aug 2026 06:42:05 -0400

Canaccord analyst Whitney Ijem raised the price target on Pharming Group (NASDAQ: PHAR) to $38.00 (from $37.00) while maintaining a Buy rating.

StreetInsider.com News Articles

Form 6-K Pharming Group N.V. For: Oct 14

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Form 6-K Pharming Group N.V. For: Sep 29

Pharming CEO steps down; interim co-CEOs named

Pharming announces CEO transition

Pharming announces CEO transition

Form 6-K Pharming Group N.V. For: Sep 25

FDA accepts Pharming's sNDA for Joenja in lower-weight children

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Canaccord Reiterates Buy Rating on Pharming Group (PHAR)

Form 6-K Pharming Group N.V. For: Sep 22

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Form 6-K Pharming Group N.V. For: Sep 11

FDA approves Pharming's Joenja for children ages 4 to 11 with APDS

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Pharming Group to participate in September investor conferences

Pharming Group to participate in September investor conferences

Form 6-K Pharming Group N.V. For: Aug 13

Form 6-K Pharming Group N.V. For: Aug 13

Form 6-K Pharming Group N.V. For: Aug 13

Pharming Group (PHAR) PT Raised to $38 at Canaccord